Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism

Hiroyuki Hanada, Satomi Mugii, Manabu Okubo, Ikuhiro Maeda, Kazuya Kuwayama, Yoh Hidaka, Rika Kitazume-Taneike, Taiji Yamashita, Ryota Kawase, Hajime Nakaoka, Miwako Inagaki, Miyako Yuasa-Kawase, Kazuhiro Nakatani, Kazumi Tsubakio-Yamamoto, Daisaku Masuda, Tohru Ohama, Akifumi Matsuyama, Masato Ishigami, Makoto Nishida, Issei KomuroShizuya Yamashita

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Apolipoprotein B-48 (apoB-48) is a constituent of chylomicron remnants synthesized in the small intestines. The serum concentration of apoB-48 at fasting has been reported to be a marker of postprandial hyperlipidemia, a presumed risk factor for atherosclerosis. Methods: We evaluated the basal performance of a recently developed chemiluminescent enzyme immunoassay (CLEIA). We also examined the correlations between serum apoB-48 concentrations and other lipid concentrations or life style patterns, including smoking and drinking. We analyzed the data of 273 clinical samples by multiple regression analysis to examine the influence of other serum lipid values, age, sex, smoking, drinking status and BMI on serum apoB-48 values. Results: Within-run and between-run precision was obtained with 1.7-2.7% and 1.2-7.3%, respectively. The correlativity of enzyme-linked immunosorbent assay was correlation coefficient r = 0.953, and regression y = 1.02 × -1.59. Serum apoB-48 concentrations were higher in males than in females, and were correlated with the status of smoking as well as with remnant-like particle-cholesterol (RLP-C) concentrations. Patients with the metabolic syndrome showed higher values of serum apoB-48 compared with control subjects. Conclusion: Serum apoB-48 measurement by CLEIA was satisfactory for clinical use to assess abnormalities in the chylomicron remnant metabolism.

Original languageEnglish
Pages (from-to)160-165
Number of pages6
JournalClinica Chimica Acta
Volume413
Issue number1-2
DOIs
Publication statusPublished - 18-01-2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism'. Together they form a unique fingerprint.

  • Cite this

    Hanada, H., Mugii, S., Okubo, M., Maeda, I., Kuwayama, K., Hidaka, Y., Kitazume-Taneike, R., Yamashita, T., Kawase, R., Nakaoka, H., Inagaki, M., Yuasa-Kawase, M., Nakatani, K., Tsubakio-Yamamoto, K., Masuda, D., Ohama, T., Matsuyama, A., Ishigami, M., Nishida, M., ... Yamashita, S. (2012). Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clinica Chimica Acta, 413(1-2), 160-165. https://doi.org/10.1016/j.cca.2011.09.013